JPM Hong Kong is pretty focused on healthcare. Apart from that, a number of middle market firms in that range in sell-side. From what I remember faintly, Cain Bros SF and Cowen and Company are also leading in healthcare. Haven't heard of a strong rep from Wells Fargo SF.
GoldenCinderblock: "I keep spending all my money on exotic fish so my armor sucks. Is it possible to romance multiple females? I got with the blue chick so far but I am also interested in the electronic chick and the face mask chick."
Dunno about biotech specifically, but if you're narrowing down to specific Biotech coverage, I doubt you'd find many banks doing so. Even if they would, they wouldn't hire a guy rightaway out of undergrad SPECIFICALLY for the biotech group (you'll have to go through the generalist process and yada yada), or you could hedge your bets and luck out too. Best bet is to go for pharma focused groups.
Note, I'm advising coming from the same problems as you. I once focused on just biotech groups and did not get selected in any banks for internships. Ended up going into an engineering intern that summer. Which sucked. Don't want to get into that quagmire.
GoldenCinderblock: "I keep spending all my money on exotic fish so my armor sucks. Is it possible to romance multiple females? I got with the blue chick so far but I am also interested in the electronic chick and the face mask chick."
I've seen biotech in Boston offices for a few banks; Piper, Baird off the top of my head. There are a lot of boutiques out there too (Leerink, JSB, Backbay Life Sciences, etc). If you're really that passionate about biotech, theres a lot of consulting for Biotech out there as well. I dont think there are many big banks with groups specifically covering biotech companies, mostly its just HC groups that cover all verticals.
Agree with this. Boston is great for healthcare opportunities, while SF banks are just too hard to get into, considering everyone's behind tech and HC in Cal. Ideally though, you should be looking at where your school is to maximize chances.
GoldenCinderblock: "I keep spending all my money on exotic fish so my armor sucks. Is it possible to romance multiple females? I got with the blue chick so far but I am also interested in the electronic chick and the face mask chick."
Cantor is actually making a huge push up after they hired Sage Kelly. They just recently started building out the research arm by drawing over some big name analysts and brought over Barclays head of US equities to lead their global equities business unit.
I would def shoot for going there because no doubt orgies and, for the more senior crowd, wifeswaps, will be included in your comp package.
I didn't know about this. When did Cantor become a fuckshow? Thought they became real solemn after 9/11.
GoldenCinderblock: "I keep spending all my money on exotic fish so my armor sucks. Is it possible to romance multiple females? I got with the blue chick so far but I am also interested in the electronic chick and the face mask chick."
I've heard of the shit culture at WFC in general (not encouraging of exits, too slow and hierarchial compared to other firms), but not heard of it being a strong biotech shop. Usual names are MS, Laz and JPM, though I may also be wrong/underexposed.
GoldenCinderblock: "I keep spending all my money on exotic fish so my armor sucks. Is it possible to romance multiple females? I got with the blue chick so far but I am also interested in the electronic chick and the face mask chick."
leerink jeffries Cowen are all really good. cantor is doing really well getting exclusive book runner on a lot of deals, but the word on the street is that the VC's are getting upset with Cantor for selling bought deals. A lot of their clients wont be banking with them again.
FYI, this is a SF perspective. Can't believe no one mentioned CV... CV has been killing it in biotech the past few years; I would say CV is the current leader (coming from someone heading into a life sciences HC team that's not CV). JPM LAZ and GS (WRA) are strong too.
Impedit dolorem nihil voluptatem ab. Minima nobis et libero cumque ut. Aperiam quod sit commodi illum quibusdam cupiditate illo. Quo omnis commodi alias rem neque omnis sed.
Ducimus et explicabo labore veritatis cupiditate quo. Et vitae veritatis facere. Nihil et alias sint est explicabo voluptatum id sit. Dolorum omnis nam velit tenetur molestiae est omnis eveniet. Quos delectus cupiditate saepe harum numquam delectus. Dicta magnam ipsam quam. Recusandae non reiciendis sint omnis est.
Asperiores ab ea ut sed ut incidunt nisi. Aliquid ipsa unde et et. Excepturi ex odit esse voluptatem sit doloremque sit. Quia amet eum minima rerum.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
Aut iste quod sit qui ex iusto enim. Quas sint delectus eos ut non aut voluptatibus. Rerum necessitatibus quibusdam dignissimos voluptatem voluptatum et. Ut rem aliquid et dolores.
Quis praesentium beatae assumenda odit facilis beatae. Incidunt deleniti autem sint molestiae esse. Nobis at sunt omnis alias veniam. Quis non possimus aut est laudantium aspernatur. Et quaerat magni rem ea beatae porro ducimus eaque.
Reiciendis animi iure eum adipisci dolor ut. Enim doloribus repellat natus.
Sorry, you need to login or sign up in order to vote. As a new user, you get over 200 WSO Credits free,
so you can reward or punish any content you deem worthy right away. See you on the other side!
JPM Hong Kong is pretty focused on healthcare. Apart from that, a number of middle market firms in that range in sell-side. From what I remember faintly, Cain Bros SF and Cowen and Company are also leading in healthcare. Haven't heard of a strong rep from Wells Fargo SF.
Thanks! But do they also cover Biotech in HK?
I know Cain's pretty strong in HC, but they do not cover Biotech (yet), only pharma and services...
Dunno about biotech specifically, but if you're narrowing down to specific Biotech coverage, I doubt you'd find many banks doing so. Even if they would, they wouldn't hire a guy rightaway out of undergrad SPECIFICALLY for the biotech group (you'll have to go through the generalist process and yada yada), or you could hedge your bets and luck out too. Best bet is to go for pharma focused groups.
Note, I'm advising coming from the same problems as you. I once focused on just biotech groups and did not get selected in any banks for internships. Ended up going into an engineering intern that summer. Which sucked. Don't want to get into that quagmire.
I've seen biotech in Boston offices for a few banks; Piper, Baird off the top of my head. There are a lot of boutiques out there too (Leerink, JSB, Backbay Life Sciences, etc). If you're really that passionate about biotech, theres a lot of consulting for Biotech out there as well. I dont think there are many big banks with groups specifically covering biotech companies, mostly its just HC groups that cover all verticals.
Agree with this. Boston is great for healthcare opportunities, while SF banks are just too hard to get into, considering everyone's behind tech and HC in Cal. Ideally though, you should be looking at where your school is to maximize chances.
For Piper HC in Mpls is broken up into 3 verticals: medtech, HCIT, biopharm/biotech.
Thought their main biopharma office was NYC though...whats in MPLS?
Pretty confident Baird does not have a IBD office in Boston. Piper's office is like 10 ppl only doing Tech.
They have 2 IBD positions in Boston listed on their website right now.
They most definitely have a life sciences office in Boston.
Would add Cowen and Leerink to the boutique list.
Cantor is actually making a huge push up after they hired Sage Kelly. They just recently started building out the research arm by drawing over some big name analysts and brought over Barclays head of US equities to lead their global equities business unit.
I would def shoot for going there because no doubt orgies and, for the more senior crowd, wifeswaps, will be included in your comp package.
I didn't know about this. When did Cantor become a fuckshow? Thought they became real solemn after 9/11.
In SF, Wells Fargo is strong in biotech -- but I know someone who worked there and was basically a slave.
I've heard of the shit culture at WFC in general (not encouraging of exits, too slow and hierarchial compared to other firms), but not heard of it being a strong biotech shop. Usual names are MS, Laz and JPM, though I may also be wrong/underexposed.
leerink jeffries Cowen are all really good. cantor is doing really well getting exclusive book runner on a lot of deals, but the word on the street is that the VC's are getting upset with Cantor for selling bought deals. A lot of their clients wont be banking with them again.
http://www.roth.com
Roth hc team just left for op. Co
FYI, this is a SF perspective. Can't believe no one mentioned CV... CV has been killing it in biotech the past few years; I would say CV is the current leader (coming from someone heading into a life sciences HC team that's not CV). JPM LAZ and GS (WRA) are strong too.
Also, just to answer your question on whether GS WRA covers biotech--yes they do. Have a friend who worked there this summer.
Impedit dolorem nihil voluptatem ab. Minima nobis et libero cumque ut. Aperiam quod sit commodi illum quibusdam cupiditate illo. Quo omnis commodi alias rem neque omnis sed.
Ducimus et explicabo labore veritatis cupiditate quo. Et vitae veritatis facere. Nihil et alias sint est explicabo voluptatum id sit. Dolorum omnis nam velit tenetur molestiae est omnis eveniet. Quos delectus cupiditate saepe harum numquam delectus. Dicta magnam ipsam quam. Recusandae non reiciendis sint omnis est.
Asperiores ab ea ut sed ut incidunt nisi. Aliquid ipsa unde et et. Excepturi ex odit esse voluptatem sit doloremque sit. Quia amet eum minima rerum.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...
Aut iste quod sit qui ex iusto enim. Quas sint delectus eos ut non aut voluptatibus. Rerum necessitatibus quibusdam dignissimos voluptatem voluptatum et. Ut rem aliquid et dolores.
Quis praesentium beatae assumenda odit facilis beatae. Incidunt deleniti autem sint molestiae esse. Nobis at sunt omnis alias veniam. Quis non possimus aut est laudantium aspernatur. Et quaerat magni rem ea beatae porro ducimus eaque.
Reiciendis animi iure eum adipisci dolor ut. Enim doloribus repellat natus.